Intensity Therapeutics, Inc. Common stock (INTS NASDAQ) stock market data APIs
$0.3014
0.01(3.3%)
as of July 2, 2025
Try our APIs with
free plan!
Intensity Therapeutics, Inc. Common stock Financial Data Overview
Price chart is built with
Anychart
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Prev. Close
0.3014
Open
0.3132
High
0.3132
Low
0.2935
52 wk Range
0.2602-5.1
Market Cap
7 822 K
Shares Outstanding
26 075 K
EPS
-0.22
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Intensity Therapeutics, Inc. Common stock data using free add-ons & libraries
Get Intensity Therapeutics, Inc. Common stock Fundamental Data
Intensity Therapeutics, Inc. Common stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Intensity Therapeutics, Inc. Common stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.18
Get Intensity Therapeutics, Inc. Common stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Intensity Therapeutics, Inc. Common stock News
New
Intensify Therapeutics slumps 27%, prices $2M stock offering
* Intensity Therapeutics (NASDAQ:INTS [https://seekingalpha.com/symbol/INTS]) stock price slumped 27% on Wednesday during after market hours of trading as it priced [https://seekingalpha.com/pr/2013...
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
Company poised to accelerate accrual in all clinical programs as it activates numerous sites across multiple U.S. cities and abroad and takes over sponsorship from the investigator-led program Updated...
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
Portage Biotech, Inc. Company poised to accelerate accrual in all clinical programs as it activates numerous sites across multiple U.S. cities and abroad and takes over sponsorship from the investiga...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
